BioCentury | Dec 15, 2020

Prevail acquisition affords Lilly an ‘entry point’ in gene therapy, with more deals likely to follow

...showcased biomarker data showing normalized levels of glucocerebrosidase...
BioCentury | Oct 2, 2020

From Termeer to scuttled Allergan deal, Lysosomal’s winding road continues with Bial takeout

...Phase II testing in 2021.TARGETSGBA (GCase) – glucocerebrosidase Virginia...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

...Phase II testing to treat a subset of patients with Parkinson’s disease who harbor a glucocerebrosidase...
BioCentury | Jun 20, 2019
Financial News

New listings push IPO pace ahead of last year’s

...Fire After Pricing Upsized IPO” ). Targets: FGF21 - Fibroblast growth factor 21; GBA1 - Glucocerebrosidase Paul...
BioCentury | Aug 1, 2018
Distillery Therapeutics


...include additional preclinical testing of the postnatal gene therapy in models of Gaucher disease. TARGET/MARKER/PATHWAY: Glucocerebrosidase...
...2018 doi:10.1038/s41591-018-0106-7 CONTACT: Simon N. Waddington, University College London, London, U.K. email: Jennie Walters University College London Glucocerebrosidase...
BioCentury | Jul 17, 2018
Preclinical News

Fetal gene therapy could treat neurodegenerative disease

...according to a Nature Medicine paper from University College London researchers and colleagues. Mutations in glucocerebrosidase...
BioCentury | Jun 13, 2018
Distillery Therapeutics


...modulator, in Phase I testing for mitochondrial disease. TARGET/MARKER/PATHWAY: Nicotinamide adenine dinucleotide (NAD + ); glucocerebrosidase...
...German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany email: Claire Quang German Center for Neurodegenerative Diseases Helmholtz Association Glucocerebrosidase...
BioCentury | Mar 9, 2018

Genetics prevail

...founded by OrbiMed’s Jonathan Silverstein to invest in therapeutics for Parkinson’s disease patients carrying a glucocerebrosidase...
BioCentury | Feb 2, 2018

Building momentum

...and cystinosis candidate AVR-RD-04. The company licensed AVR-RD-02, which comprises stem cells engineered to express glucocerebrosidase...
BioCentury | Feb 1, 2018
Financial News

Cell therapy play Avrobio raises $60M

...disease candidate AVR-RD-02 and cystinosis candidate AVR-RD-04. AVR-RD-02 comprises hematopoietic stem cells engineered to express glucocerebrosidase...
Items per page:
1 - 10 of 269